The world of weight management is evolving faster than ever, and a new drug discovery is setting a historic milestone for obesity treatment. Eli Lilly recently announced highly encouraging results from its Phase 3 clinical trial for Retatrutide, a weekly injection that is already turning heads. CNBC reports that in an 80-week study involving 2,500 participants, those on the highest dose lost an average of 28.3% of their body weight, amounting to more than 70 pounds per person.

What truly makes Retatrutide a game-changer is that its effectiveness goes well beyond popular current options like Wegovy and Mounjaro. By helping patients shed nearly a third of their body weight, this medication delivers results previously achievable only through weight-loss surgery. As it moves closer to regulatory approval, Retatrutide promises to open up a powerful, non-surgical frontier for treating obesity safely and effectively.

How Retatrutide works

The complex biochemical design of retatrutide, with its multiple targets, is what makes it so effective. Current obesity drugs mimic one or two gut hormones that regulate appetite. Novo Nordisk’s Ozempic and Wegovy mimic only GLP-1 (glucagon-like peptide-1), notes a PMC publication, while Eli Lilly’s Zepbound mimics both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

Retatrutide is a first-of-its-kind “triple agonist” or “triple G” molecule, according to the National Institutes of Health (NIH). It mimics three metabolic hormones simultaneously: GLP-1, GIP, and glucagon. GLP-1 and GIP act together to slow stomach emptying and signal to the brain that the body is very, very full, but it’s the third hormone, glucagon, that makes the difference.

Glucagon acts directly on receptors in the liver to increase energy expenditure, creating an extra “thermostat” in the body that burns more calories even at rest.

Common side effects

As retatrutide binds with many hormone receptors in the digestive system, side effects are likely to occur, particularly as the body adapts to the drug.

The most recent clinical trial revealed that the majority of side effects are gastrointestinal, similar to other weight-loss injections, but are more common with higher doses. These symptoms tend to be greatest during the dose-upstage, when patients switch to higher doses.

Gastrointestinal distress and UTIs aren’t uncommon for Retatrutide users

Nausea was the most widely reported side effect in the trial, affecting roughly 42% of patients on the highest dose of the medication. Additionally, 32% of participants experienced diarrhea, and 26.1% suffered from constipation, according to CNBC. These symptoms are a direct byproduct of the drug slowing down gastrointestinal transit times.

“Unexpectedly, more than 8% of patients on the highest dose developed a urinary tract infection during the trial,” adds Tunde Rasheed, B.Sc. Researcher. “While these infections were mild and easily resolved with standard treatment, researchers hypothesize that this side effect is not a direct reaction to the chemical itself but rather a byproduct of the extreme ‘velocity’ of the weight loss, a phenomenon also frequently observed in patients recovering from bariatric surgery.”

Rare or serious side effects

Eli Lilly said there were no significant cardiac or liver-related problems in this particular 80-week study. Still, retatrutide has risks for rare and unique adverse events that need careful clinical monitoring.

The most common side effect associated with this highest dose was dysesthesia, an abnormal sensation in the nerves that can cause unexplained skin sensitivity, tingling or burning, in about 12% of patients.

In addition, more than 13% of the participants had upper respiratory tract infections. Endocrinologists also closely monitor heart rate because there is a theoretical risk of a transient, mild elevation or low-grade arrhythmias with triple agonists, as glucagon receptors are also expressed in the heart. None were, however, identified as major in this main cohort of obesity.

What to do if you notice symptoms

If you are a participant in an open-label trial or eventually prescribe this medication once it hits the commercial market, managing side effects early is crucial to staying on track. For mild to moderate nausea or diarrhea, doctors suggest eating smaller portions more frequently and avoiding heavy, greasy or overly sweet foods, which can slow stomach emptying.

If, however, you have severe and persistent vomiting, intense abdominal pain that spreads to the back (a possible sign of pancreatitis), or a persistently racing heart rate when you are at rest, you should contact your healthcare provider or seek emergency treatment right away.

Alternatives

Although retatrutide is the new frontier in obesity management, there are still many effective, FDA-approved pharmaceutical options available to patients today, as well as important lifestyle foundations.

According to the Mayo Clinic, current frontline options like tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy/Ozempic) remain highly reliable, offering 15% to 22% weight loss with lower rates of gastrointestinal side effects.

Any medical intervention must be accompanied by extensive lifestyle changes for sustainable long-term success. This can involve a healthy diet, regular weight-lifting exercises to help maintain muscle mass and behavioral therapy to help change emotional eating habits.

How much does Retatrutide cost per month?

An exact commercial retail price for patients has not been determined yet as Retatrutide is in the early stages of clinical trials (Phase 3) and is awaiting official FDA review and approval. This period of regulatory delay leaves health care providers and eager consumers wondering what the real price will be.

Therefore, industry analysts are forced to look at the current market for clues, predicting it will be close to the price of, or perhaps a bit dearer than, current products such as Zepbound and Wegovy. Manufacturers often use these highly successful weight-loss treatments as benchmarks to gain a competitive advantage when developing next-generation therapies.

This translates into higher out-of-pocket costs for consumers, as these drugs currently cost $1,000 to $1,350 per month before insurance coverage or manufacturer savings cards. These are not small monthly costs, and until the new drug is on a company’s formulary, it will be a significant financial burden.

What is the best diet while taking Retatrutide?

The ideal dietary framework when taking retatrutide is a high-protein, whole-food diet focused on lean proteins (such as chicken, fish and tofu), fibrous vegetables and healthy fats. Prioritizing protein is essential because rapid weight loss can cause the body to burn through muscle tissue; consuming adequate protein, paired with resistance training, ensures that the weight you lose comes from body fat rather than lean muscle.

“This latest data only confirms what I’ve seen in my clinic: We’re not gaining weight because we stopped moving. We’re gaining because we’re overfed,” says Lindsay Allen, a registered dietitian nutritionist and owner of Back in Balance Nutrition in Florida.

Bottom line

Retatrutide is a groundbreaking, next-generation “triple G” weight loss injection that mimics three gut hormones to suppress appetite and elevate metabolism, clearing a historic 2026 Phase 3 trial with a surgery-like 28.3% average weight loss. While higher doses provoke notable gastrointestinal side effects and a higher frequency of mild UTIs, lower doses offer an incredibly well-tolerated alternative that matches the strongest drugs currently on the market. Once approved, this triple-agonist molecule will be a monumental pillar in the global fight against clinical obesity and its associated cardiovascular risks.

Frequently Asked Questions

How quickly does Retatrutide work?

Retatrutide begins suppressing appetite and altering metabolic rate within the first week after the initial injection, with significant, measurable weight reduction that accumulates steadily over the first few months.

Is Retatrutide better than Ozempic?

Clinical data indicate that retatrutide is significantly more effective than Ozempic, achieving an average weight loss of 28% over 80 weeks, compared to roughly 15% with Wegovy, Ozempic’s weight-loss counterpart.

Citations

Constantino AK. Eli Lilly says next-generation weight loss drug clears crucial obesity trial. CNBC. Published May 21, 2026. https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html

Wojtara MS, Mazumder A, Syeda Y, Mozgała N. Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management. Advances in Medicine. 2023;2023:1-7. doi:https://doi.org/10.1155/2023/9946924

Alqatari SG, Alwaheed AJ, Hasan MA, Argan A, Alabdullah MM, Al MD. Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines. Medicina. 2025;61(7):1292-1292. doi:https://doi.org/10.3390/medicina61071292

Mayo Clinic Staff. Pros and cons of weight-loss drugs. Mayo Clinic. Published October 29, 2022. https://www.mayoclinic.org/healthy-lifestyle/weight-loss/in-depth/weight-loss-drugs/art-20044832